Genomic News and Research

RSS

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

NEB announces issuance of US patent for RNA-seq technology

New England Biolabs, Inc. announces the issuance of United States Patent Number 8,999,677, which describes a novel method for retaining valuable strand-specific information contained within RNA transcripts.

From New England Biolabs 6 May 2015

Relaxation response has significant impact on patients with gastrointestinal disorders

A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.

6 May 2015

Max Planck Institute researchers find protein profiles of DNA repair

During each cell division, more than 3.3 billion base pairs of genomic DNA have to be duplicated and segregated accurately to daughter cells. But what happens when the DNA template is damaged in such a way that the replication machinery gets stuck? To answer this question, scientists in the team of Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried near Munich, with colleagues in Copenhagen and at Harvard, have analyzed how the protein composition of the DNA replication machinery changes upon encountering damaged DNA.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Chromatrap®, a business unit of Porvair Sciences, has published a new application note that describes how Chromatrap® ChIP-seq assays now enable unbiased, genome-wide understanding of protein-DNA regulatory networks...

From Chromatrap® - Porvair Sciences Ltd 30 Apr 2015

Patients with traumatic brain injuries need effective cognitive neuroscience-based therapies

Patients with traumatic brain injuries are not benefiting from recent advances in cognitive neuroscience research - and they should be, scientists report in a special issue of Current Opinion in Behavioral Sciences.

30 Apr 2015

New genetic mutation appears to protect people from Type 2 diabetes

An international team of scientists led by a Cedars-Sinai researcher has identified a new genetic mutation that appears to protect people from developing Type 2 diabetes.

29 Apr 2015

IDT opens molecular biology R&D facility in Redwood City

Already the world’s leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.

From Integrated DNA Technologies 28 Apr 2015

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway.

From Luminex 28 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Common diabetes medication causes intersex in fish

A medication commonly taken for Type II diabetes, which is being found in freshwater systems worldwide, has been shown to cause intersex in fish -male fish that produce eggs.

27 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

EMD Millipore launches Magna ChIRP RNA Interactome Kits for analyzing chromatin-associated RNAs

EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Magna ChIRP™ RNA Interactome Kits, which allow researchers to more easily identify, recover and analyze regions of chromatin that interact with chromatin-associated RNAs such as long non-coding RNA (lncRNA).

23 Apr 2015

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

23 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year agreement, Scripps will work with UC San Diego to provide outpatient and inpatient hospice care for UC San Diego patients, allowing UC San Diego physicians to better coordinate post-acute care for patients with chronic illness.

23 Apr 2015

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins.

22 Apr 2015

Genomic News and Research

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

NEB announces issuance of US patent for RNA-seq technology

Relaxation response has significant impact on patients with gastrointestinal disorders

Max Planck Institute researchers find protein profiles of DNA repair

Researchers identify multiple types of resistance to new targeted lung cancer drug

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Patients with traumatic brain injuries need effective cognitive neuroscience-based therapies

New genetic mutation appears to protect people from Type 2 diabetes

IDT opens molecular biology R&D facility in Redwood City

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

PCDx test performs better than FoundationOne test in clinical study

Molecular Health granted European patent for novel Erythropoietin receptor

Common diabetes medication causes intersex in fish

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

EMD Millipore launches Magna ChIRP RNA Interactome Kits for analyzing chromatin-associated RNAs

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

ADCs based on alpha-amanatin may help treat colorectal cancer

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Genetics & Genomics - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News